Dr Angelica Loskog speaks to ecancer about results from the LOKON001 study evaluating LOAd703, a tumour-selective oncolytic adenovirus, in combination with chemotherapy and atezolizumab in patients with advanced pancreatic cancer.

LOAd703 is designed to reprogram the tumour microenvironment and enhance anti-tumour immune responses.

When combined with nab-paclitaxel, gemcitabine, and atezolizumab, the regimen demonstrated encouraging clinical activity, including meaningful response rates and durable disease control, particularly in the first-line setting where complete responses were observed.

The treatment was generally well tolerated, with mostly low-grade, manageable side effects such as fever and fatigue.

Molecular analyses further supported its mechanism, showing activation of adaptive immune pathways associated with response and survival.

Dr Loskog says that these findings suggest that LOAd703-based combination therapy may represent a promising immunotherapy strategy in pancreatic cancer and support further evaluation in randomised trials.